Suivi thérapeutique des médicaments (II). La pratique clinique [Therapeutic drug monitoring: clinical practice].


Autoria(s): Widmer N.; Werner D.; Grouzmann E.; Eap C.B.; Marchetti O.; Fayet A.; Csajka C.; Decosterd L.A.; Buclin T.
Data(s)

2008

Resumo

When requesting a blood level measurement in the context of "Therapeutic drug monitoring" (TDM), numerous aspects have to be considered in the pre-analytical and analytical area, as in the integration of associated clinical data. This review presents therapeutic classes for which a clinical benefit of TDM is established or suggested, at least in some settings. For each class of drugs, the main pharmacokinetic, pre-analytical, analytical and clinical aspects are evaluated in the scope of such a monitoring. Each step of the TDM process is important and none should be neglected. Additional clinical trials are however warranted to better establish the exact conditions of use for such a monitoring.

Identificador

http://serval.unil.ch/?id=serval:BIB_53F56A1C36B3

isbn:1660-9379 (Print)

pmid:18767291

Idioma(s)

fr

Fonte

Revue Médicale Suisse, vol. 4, no. 165, pp. 1649-1660

Palavras-Chave #Anti-Bacterial Agents/blood; Anti-Bacterial Agents/pharmacokinetics; Anti-Retroviral Agents/blood; Anti-Retroviral Agents/pharmacokinetics; Anticonvulsants/blood; Anticonvulsants/pharmacokinetics; Antineoplastic Agents/blood; Antineoplastic Agents/pharmacokinetics; Antiparasitic Agents/blood; Antiparasitic Agents/pharmacokinetics; Antitubercular Agents/blood; Antitubercular Agents/pharmacokinetics; Cardiovascular Agents/blood; Cardiovascular Agents/pharmacokinetics; Dose-Response Relationship, Drug; Drug Monitoring/methods; Drug Monitoring/standards; Evidence-Based Medicine; Humans; Immunosuppressive Agents/blood; Immunosuppressive Agents/pharmacokinetics; Product Surveillance, Postmarketing; Psychotropic Drugs/blood; Psychotropic Drugs/pharmacokinetics
Tipo

info:eu-repo/semantics/review

article